Cavity Fluid Accumulation Syndrome in Patients with COVID-19 Coronavirus Infection
The retrospective study of patients with COVID-19 coronavirus infection identifies possible causes of fluid accumulation in various serous cavities and compares the presence of fluid accumulation syndrome in cavities with the severity of the course of coronavirus infection. A total of 85 charts of inpatients treated at the Kabanov A.N. Municipal Clinical Hospital No. 1 for confirmed coronavirus infection were studied. They were divided into 2 groups: 1st – having a syndrome of effusion in one or more cavities (pleuritis, pericarditis and/or ascites): 48 patients; 2nd group ̵ not having pleural effusion syndrome: 37 patients. The data obtained in the study showed that the causes of fluid accumulation in serous cavities in patients with COVID-19 are hypoproteinemia and concomitant diseases running with general edema, more often it is chronic kidney disease stage 3 or more, liver cirrhosis, malignant tumors of different localization. Taking into account that vital function indices were comparable in the studied groups, we assumed that pleural effusion syndrome in COVID-19 patients in general does not aggravate the course of the disease, except for rare isolated cases with massive effusions into the pleural or pericardial cavity. Taking into account the obtained results, attention to early correction of hypoproteinemia and active detection of concomitant pathology in COVID-19 patients with cavity fluid accumulation syndrome is justified.
Zamakhina O.V., Kanevskaya S.S., Genatov A.B., Osipenko E.V., Zhernakova N.I. 2023. Cavity Fluid Accumulation Syndrome in Patients with COVID-19 Coronavirus Infection. Challenges in Modern Medicine, 46(4): 321–332 (in Russian). DOI: 10.52575/2687-0940-2023-46-4-321-332
While nobody left any comments to this publication.
You can be first.
Vatutin N.T., Taradin G.G., Rakitskaya I.V. 2020. Emergency conditions in cardiology (lecture). Bulletin of urgent and recovery surgery. 5(2): 21–37. https://doi.org/10.33667/2078-5631-2021-11-60-64
Gribanov V.P., Kirillov A.S., Vavilov I.A., Ozerova E.D., Lomaichikov V.V. 2021. Acute pericarditis in patient with COVID 19: pre-hospital and in-hospital follow-up stages. Medical alphabet. 11: 60–63 (in Russian). https://doi.org/10.33667/2078-5631-2021-11-60-64
Lesnyak V.N., Zhuravleva V.A., Averyanov A.V. 2020. The Capabilities of MRI in the Lung Lesions Diagnosis in Patients with COVID-19. Journal of Clinical Practice. 11(2): 51–59. doi: 10.17816/clinpract34843
Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19). 2021. Temporary guidelines. Version 14. Ministry of Health of the Russian Federation (in Russian). URL: https://fnkcrr.ru/wp-content/uploads/2021/12/v14-covid-metodic.pdf
Reznik V.I., Savosina L.V., Lebedeva L.A., Zhaleico Z.P., Garbuz Yu.A., Prisyazhnuk E.N. 2023. Etiological peculiarities of ari epidemic process n modern conditions. Far Eastern Journal Infectious Pathology. 44(44): 30–35.
2015 ESC guidelines for the diagnosis and management of pericardial diseases. Russ. J. Cardiol. 2016, 5(133): 117–162 (in Russian). http://dx.doi.org/10.15829/1560-4071-2016-5-117-162.
Salimov D.S., Glushkov I.V., Vorobev A.A., Kraynukov P.E. 2022. Pleura damage in COVID-19, experience of treatment during eighteen months of the pandemic. Russian Journal of Operative Surgery and Clinical Anatomy. 6(2): 26–31. https://doi.org/10.17116/operhirurg2022602126
Ter-Bagdasaryan L.V., Ratnikova L.I., Lebedeva E.YU., Sychugov G.V., Ivanova A.V., Pirigov D.V., Nikulina K.A., Lokteva M.A. 2022. Description of the clinical picture of COVID-19 in patients with fatal outcome. Infectious diseases: News, Opinions, Training. 11(3): 52–60 (in Russian). doi: https://doi.org/10.33029/2305-3496-2022-11-3-52-60
Buckley L.F., Viscusi M.M., Van Tassell B.W., Abbate A. 2018. Interleukin-1 blockade for the treatment of pericarditis. Eur Heart J Cardiovasc Pharmacother. 4(1):46–53. doi: 10.1093/ehjcvp/pvx018
Chong W.H., Saha B.K., Conuel E., Chopra A. 2021. The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review. Heart Lung. 50(4):481-490. doi: 10.1016/j.hrtlng.2021.02.015.
European Association for the Study of the Liver. 2018. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 69(2):406-460. doi: 10.1016/j.jhep.2018.03.024.
Hara K., Yamasaki K., Tahara M., Ikegami H., Nishida C., Muramutsu K., Fujino Y., Matsuda S., Fushimi K., Mukae H., Yatera K. 2022. Epidemiologic evaluation of pleurisy diagnosed by surgical pleural biopsy using data from a nationwide administrative database. Thorac Cancer. 13(8):1136-1142. doi: 10.1111/1759-7714.14368.
Helliksson F., Wernerman J., Wiklund L., Rosell J., Karlsson M. 2016. The combined use of three widely available biochemical markers as predictor of organ failure in critically ill patients. Scandinavian Journal of Clinical and Laboratory Investigation. 76(6):479-485. https://doi.org/10.1080/00365513.2016.1201850
Jabbar A., Qureshi R., Nasir K., Dhrolia M., Ahmad A. 2021. Transudative and Exudative Pleural Effusion in Chronic Kidney Disease Patients: A Prospective Single-Center Study. Cureus. 13(10):e18649. doi:10.7759/cureus.18649
Jhala N., Jhala D., Shidham V.B. 2022. Serous fluid: Reactive conditions. Cytojournal. 19(14). doi:10.25259/CMAS_02_06_2021.
Kermani-Alghoraishi M., Pouramini A., Kafi F., Khosravi A. 2022. Coronavirus Disease 2019 (COVID-19) and Severe Pericardial Effusion: From Pathogenesis to Management: A Case Report Based Systematic Review. Curr Probl Cardiol. 47(2):100933. doi: 10.1016/j.cpcardiol.2021.100933.
Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J., Pose E., Brenner E.J., Cargill T., Catana M.A., Dhanasekaran R., Eshraghian A., García-Juárez I., Gill U.S., Jones P.D., Kennedy J., Marshall A., Matthews C., Mells G., Mercer C., Perumalswami P.V., Avitabile E., Qi X., Su F., Ufere N.N., Wong Y.J., Zheng M.H., Barnes E., Barritt A.S., Webb G.J. 2021. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 74(3):567-577. doi: 10.1016/j.jhep.2020.09.024.
Marjot T., Webb G.J., Barritt A.S., Moon A.M., Stamataki Z., Wong V.W., Barnes E. 2021. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 18(5):348-364. doi: 10.1038/s41575-021-00426-4.
Muhie O.A. 2019. Causes and Clinical Profiles of Ascites at University of Gondar Hospital, Northwest Ethiopia: Institution-Based Cross-Sectional Study. Can J Gastroenterol Hepatol. 2019:5958032. doi: 10.1155/2019/5958032.
Sauer F., Dagrenat C., Couppie P., Jochum G., Leddet P. 2020. Pericardial effusion in patients with COVID-19: case series. Eur Heart J Case Rep. 4(FI1):1-7. doi: 10.1093/ehjcr/ytaa287
Shidham V.B., Layfield L.J. 2021. Introduction to the second edition of 'Diagnostic Cytopathology of Serous Fluids' as CytoJournal Monograph (CMAS) in Open Access. Cytojournal. 18(30). doi: 10.25259/CMAS_02_01_2021.
Soldati G., Smargiassi A., Inchingolo R. et al. Is there a role for lungultrasound during the COVID-19 pandemic? J. Ultrasound Med.2020; 39(7): 1459–1462. DOI: 10.1002/jum.15284
Sultan S., Altayar O., Siddique S.M., Davitkov P., Feuerstein J.D., Lim J.K., Falck-Ytter Y., El-Serag H.B. 2020. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 159(1):320-334. https://doi.org/10.1053/j.gastro.2020.05.001
The work was carried out without external sources of funding.